Abbott Laboratories $ABT Shares Acquired by EverSource Wealth Advisors LLC

EverSource Wealth Advisors LLC grew its stake in shares of Abbott Laboratories (NYSE:ABT) by 36.5% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 19,689 shares of the healthcare product maker’s stock after acquiring an additional 5,269 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Abbott Laboratories were worth $2,021,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Freemont Management S.A. raised its position in shares of Abbott Laboratories by 197.2% during the 4th quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock valued at $1,341,000 after buying an additional 7,100 shares in the last quarter. PFA Pension Forsikringsaktieselskab purchased a new stake in Abbott Laboratories during the fourth quarter valued at approximately $116,580,000. Thrivent Financial for Lutherans boosted its holdings in shares of Abbott Laboratories by 24.3% in the 4th quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock worth $30,931,000 after purchasing an additional 48,286 shares during the period. Aureus Asset Management LLC increased its position in shares of Abbott Laboratories by 25.0% during the 1st quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker’s stock valued at $34,078,000 after purchasing an additional 66,422 shares during the last quarter. Finally, BXM Wealth LLC raised its holdings in Abbott Laboratories by 612.7% during the 4th quarter. BXM Wealth LLC now owns 28,772 shares of the healthcare product maker’s stock valued at $3,605,000 after buying an additional 24,735 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott remains a favored income stock among analysts, with TipRanks highlighting its Dividend Aristocrat status and recurring cash distributions. 3 Strong Buy Dividend Aristocrat Stocks to Power Your Cash Flow
• Positive Sentiment: Erste Group Bank raised its fiscal 2026 EPS estimate to $5.52 from $5.47 and nudged its fiscal 2027 estimate to $6.06 from $6.05, broadly confirming consensus expectations.
• Positive Sentiment: UBS issued a Buy rating, while TD Cowen maintained its Buy rating and a $115 price target, citing a strengthening nutrition franchise and additional 2026 growth drivers. UBS Issues a Buy Rating on Abbott Laboratories Abbott Laboratories Buy Rating Backed by Growth Drivers
• Positive Sentiment: Abbott recently exceeded quarterly EPS and revenue expectations, with revenue growth of 13% year over year, supporting the case for continued earnings momentum.
• Neutral Sentiment: Abbott has begun a roughly 1,000-patient real-world TriClip study to evaluate safety and performance in heart-valve repair. The study could strengthen the product’s positioning, but it also underscores intensifying competition from Edwards. Abbott Starts TriClip Study Amid Rising Competition
• Negative Sentiment: UBS has lowered its expectations for Abbott’s stock price, creating a counterweight to the Buy rating and other positive analyst revisions. The conflicting views may be contributing to investor caution.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Weiss Ratings cut shares of Abbott Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 23rd. Leerink Partners cut their price target on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a report on Tuesday, April 21st. UBS Group decreased their price objective on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday. Raymond James Financial dropped their target price on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Finally, Barclays cut their target price on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a research note on Monday, April 20th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $118.17.

Abbott Laboratories Trading Down 2.0%

NYSE ABT opened at $105.83 on Friday. The stock has a market cap of $183.12 billion, a PE ratio of 34.25, a PEG ratio of 2.09 and a beta of 0.61. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The company’s 50-day moving average price is $93.08 and its 200-day moving average price is $100.58. The company has a current ratio of 1.38, a quick ratio of 1.01 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The company had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter last year, the business posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s payout ratio is currently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.